Company intelligence / Profile preview

ImmuneWorks

Indianapolis, Indiana, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

ImmuneWorks developed IW001, a purified bovine Type V Collagen oral solution, as an immunomodulatory therapy for idiopathic pulmonary fibrosis and primary graft dysfunction. The company received orphan drug designation and began Phase I clinical trials in collaboration with Lung Rx/United Therapeutics around 2010–2011. No further clinical results or updates are publicly available after this period, suggesting the program did not advance to later stages or commercialization.

Therapeutic areas: Pulmonology
Modalities: ProteinBiologic
Industry: Biotech

Drug pipeline

1 asset

IW001

Partnerships

Lung Rx (subsidiary of United Therapeutics Corporation)

Beyond the preview

Go deeper on ImmuneWorks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuneWorks.

Explore the full profile